US Patent Issued to Xencor on Dec. 30 for "Methods and compositions for inhibiting CD32B expressing cells in IgG4-related diseases" (California, Massachusetts Inventors)

ALEXANDRIA, Va., Dec. 31 -- United States Patent no. 12,509,518, issued on Dec. 30, was assigned to Xencor Inc. (Monrovia, Calif.).

"Methods and compositions for inhibiting CD32B expressing cells in IgG4-related diseases" was invented by Debra Zack (San Diego), John H. Stone (Boston), Shiv Pillai (Monrovia, Calif.) and Paul Foster (Monrovia, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to immunoglobulins that bind FcGammaRIIb+ B cells and coengage CD19 on the cell's surface and an FcGammaRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins for the treatment of an IgG4-related disease."

The patent was filed on May 16, 2022...